Nautilus Biotechnology Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters2023-10-27

* Nautilus Biotechnology Inc is expected to show no change in quarterly revenue when it reports results

*

* Refinitiv's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 17 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $6, above its last closing price of $2.51.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT IBES MET, SE %

E® ESTIMATE MISSED

Jun. 30 2023 -0.14 -0.15 -0.13 Beat 13.3

Mar. 31 2023 -0.16 -0.17 -0.12 Beat 28

Dec. 31 2022 -0.14 -0.15 -0.11 Beat 28.3

Sep. 30 2022 -0.15 -0.15 -0.11 Beat 25.4

Jun. -0.17 -0.17 -0.12 Beat 28.4

30 2022

Mar. 31 2022 -0.16 -0.16 -0.13 Beat 17

Dec. 31 2021 -0.14 -0.13 -0.13 Met 1.9

Sep. 30 2021 -0.10 -0.10 -0.12 Missed -20

This summary was machine generated October 27 at 18:34 GMT. All figures in US dollars unless otherwise stated.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2378832013?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2023-10-28 02:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2378832013","market":"us","top_or_hot":-1,"title":"Nautilus Biotechnology Inc expected to post a loss of 17 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* Nautilus Biotechnology Inc     is expected to show no change in quarterly revenue when it reports  results </p><p>   * </p><p>   * Refinitiv's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 17 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $6, above its last closing price of $2.51. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  IBES                 MET,    SE %</p><p>              E®          ESTIMATE             MISSED  </p><p>Jun. 30 2023  -0.14       -0.15      -0.13     Beat    13.3</p><p>Mar. 31 2023  -0.16       -0.17      -0.12     Beat    28</p><p>Dec. 31 2022  -0.14       -0.15      -0.11     Beat    28.3</p><p>Sep. 30 2022  -0.15       -0.15      -0.11     Beat    25.4</p><p>Jun.        -0.17       -0.17      -0.12     Beat    28.4</p><p>30 2022                                                </p><p>Mar. 31 2022  -0.16       -0.16      -0.13     Beat    17</p><p>Dec. 31 2021  -0.14       -0.13      -0.13     Met     1.9</p><p>Sep. 30 2021  -0.10       -0.10      -0.12     Missed  -20</p><p>This summary was machine generated October 27 at 18:34 GMT.  All figures in US dollars  unless otherwise stated.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nautilus Biotechnology Inc expected to post a loss of 17 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNautilus Biotechnology Inc expected to post a loss of 17 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-10-28 02:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>* Nautilus Biotechnology Inc     is expected to show no change in quarterly revenue when it reports  results </p><p>   * </p><p>   * Refinitiv's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 17 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $6, above its last closing price of $2.51. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  IBES                 MET,    SE %</p><p>              E®          ESTIMATE             MISSED  </p><p>Jun. 30 2023  -0.14       -0.15      -0.13     Beat    13.3</p><p>Mar. 31 2023  -0.16       -0.17      -0.12     Beat    28</p><p>Dec. 31 2022  -0.14       -0.15      -0.11     Beat    28.3</p><p>Sep. 30 2022  -0.15       -0.15      -0.11     Beat    25.4</p><p>Jun.        -0.17       -0.17      -0.12     Beat    28.4</p><p>30 2022                                                </p><p>Mar. 31 2022  -0.16       -0.16      -0.13     Beat    17</p><p>Dec. 31 2021  -0.14       -0.13      -0.13     Met     1.9</p><p>Sep. 30 2021  -0.10       -0.10      -0.12     Missed  -20</p><p>This summary was machine generated October 27 at 18:34 GMT.  All figures in US dollars  unless otherwise stated.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NAUT","symbol_name":"Nautilus Biotechnolgy, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2378832013","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2378832013","pubTimestamp":1698431727,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Nautilus Biotechnology Inc     is expected to show no change in quarterly revenue when it reports  results    *    * Refinitiv's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 17 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $6, above its last closing price of $2.51. Previous quarterly performance . QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  IBES                 MET,    SE %              E          ESTIMATE             MISSED  Jun. 30 2023  -0.14       -0.15      -0.13     Beat    13.3Mar. 31 2023  -0.16       -0.17      -0.12     Beat    28Dec. 31 2022  -0.14       -0.15      -0.11     Beat    28.3Sep. 30 2022  -0.1","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NAUT":"Nautilus Biotechnolgy, Inc."},"translate_title":"鹦鹉螺生物技术公司预计每股亏损17美分——收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFX":1,"NAUT":0.9,"NLS":1},"content_text":"* Nautilus Biotechnology Inc     is expected to show no change in quarterly revenue when it reports  results    *    * Refinitiv's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 17 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $6, above its last closing price of $2.51. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  IBES                 MET,    SE %              E®          ESTIMATE             MISSED  Jun. 30 2023  -0.14       -0.15      -0.13     Beat    13.3Mar. 31 2023  -0.16       -0.17      -0.12     Beat    28Dec. 31 2022  -0.14       -0.15      -0.11     Beat    28.3Sep. 30 2022  -0.15       -0.15      -0.11     Beat    25.4Jun.        -0.17       -0.17      -0.12     Beat    28.430 2022                                                Mar. 31 2022  -0.16       -0.16      -0.13     Beat    17Dec. 31 2021  -0.14       -0.13      -0.13     Met     1.9Sep. 30 2021  -0.10       -0.10      -0.12     Missed  -20This summary was machine generated October 27 at 18:34 GMT.  All figures in US dollars  unless otherwise stated.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2378832013"}